Changes in Hong Kong stocks | Xinwei Medical-B (06609) rose nearly 9% at the end of the session, and the steady progress of the A-share IPO process is expected to increase the company's stock liquidity

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Xinwei Medical-B (06609) rose nearly 9% at the end of the session. As of press release, it rose 8.36% to HK$61.6, with a turnover of HK$114.16,400.

According to the news, Xinwei Medical plans to submit an application for the initial public offering of A shares to the Shanghai Stock Exchange in the second half of 2026 and to be listed on the Science and Technology Innovation Board, and plans to raise about 500 million yuan in capital. It is mainly used for brain science medical device construction projects, vascular interventional medical device R&D and production projects, R&D and registration projects.

CITIC Construction Investment said that the company is steadily advancing the A-share IPO process. In the future, it is expected that capital market liquidity will be further enhanced through the A-share IPO listing, and will use the power of the capital market to further accelerate the company's commercialization layout in the global market through endogenous epitaxial methods. At the same time, the company will continue to promote stock repurchases and cash dividends in accordance with the company's business conditions and regulatory requirements.